LYON, France, September 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the upcoming Morgan Stanley 21 st
- Record second quarter and first half revenue s of EUR 14.3 million (USD 15 .5 million) and EUR 29.1 million (USD 31.5 million), respectively - - Total HIFU Q 2 2023 year - over - year revenue growth of 63. 6 % - - S trong Q 2 2023 year-over-year U.S.
- Company to host conference call and webcast on Thur sday, August 24 th at 8:30 am EDT - LYON, France, August 10, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30
LYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerland for the use of High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer.
LYON, France, May 24, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Healthcare Conference,
- Record first quarter revenue - - Positive results from two studies reconfirm safety and efficacy of Focal One - - Company to host conference call and webcast today, Wednesday, May 17 th at 8:30 am EDT - LYON, France, May 17, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic
- Company to host conference call and webcast on Wednesday, May 1 7 th at 8:30 am EDT - LYON, France, May 3, 2023 - EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended
Meeting to Showcase EDAP’s Focal One ® Robotic High Intensity Focused Ultrasound (HIFU) Platform for the Management of Prostate Cancer LYON, France, April 21, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the Company
Leading Center Demonstrates Focal HIFU as a Tool in The Management of Prostate Cancer Web cast scheduled for Tuesday, April 18 th at 12:00 p.m. PDT (3:00 p.m. EDT) LYON, France, April 10, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today
Allows for market launch of the only micro - ultrasound platform for precision prostate biopsies LYON, France, April 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today provided a regulatory and clinical update.
